These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2700694)

  • 21. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Adv Neurol; 1983; 37():277-89. PubMed ID: 6574695
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in understanding L-DOPA-induced dyskinesia.
    Cenci MA; Lindgren HS
    Curr Opin Neurobiol; 2007 Dec; 17(6):665-71. PubMed ID: 18308560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Schuster S; Doudnikoff E; Rylander D; Berthet A; Aubert I; Ittrich C; Bloch B; Cenci MA; Surmeier DJ; Hengerer B; Bezard E
    Biol Psychiatry; 2009 Mar; 65(6):518-26. PubMed ID: 18947822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine therapy for Parkinson's disease and other movement disorders.
    Pfeiffer C; Wagner ML
    Am J Hosp Pharm; 1994 Dec; 51(24):3047-53. PubMed ID: 7856623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deanol in the management of involuntary movement disorders: a review.
    Casey DE
    Dis Nerv Syst; 1977 Dec; 38(12 Pt 2):7-15. PubMed ID: 145359
    [No Abstract]   [Full Text] [Related]  

  • 30. High-dose pyridoxine in tardive dyskinesia.
    DeVeaugh-Geiss J; Manion L
    J Clin Psychiatry; 1978 Jun; 39(6):573-5. PubMed ID: 350860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinguishing akathisia and tardive dyskinesia: a review of the literature.
    Munetz MR; Cornes CL
    J Clin Psychopharmacol; 1983 Dec; 3(6):343-50. PubMed ID: 6139392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Animal models of L-DOPA-induced dyskinesia: an update on the current options.
    Iderberg H; Francardo V; Pioli EY
    Neuroscience; 2012 Jun; 211():13-27. PubMed ID: 22465440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia].
    Karniol IG; Giampietro AC; Moura DS; Vilela WA; Oliveira MA; Zuardi AW
    Acta Psiquiatr Psicol Am Lat; 1983 Dec; 29(4):261-6. PubMed ID: 6369888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphine in tardive and idiopathic dystonia (short communication).
    Berg D; Becker G; Naumann M; Reiners K
    J Neural Transm (Vienna); 2001; 108(8-9):1035-41. PubMed ID: 11716139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Movement abnormalities and their treatment in general practice].
    Gonce M; Delwaide PJ
    Rev Med Liege; 1979 Oct; 34(19):797-802. PubMed ID: 297251
    [No Abstract]   [Full Text] [Related]  

  • 39. [Long-term evaluation of tiapride in patients with various forms of dyskinesia].
    Nakajima Y; Kondo T; Narabayashi H
    No To Shinkei; 1985 Oct; 37(10):1013-9. PubMed ID: 4074571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
    Rylander D; Iderberg H; Li Q; Dekundy A; Zhang J; Li H; Baishen R; Danysz W; Bezard E; Cenci MA
    Neurobiol Dis; 2010 Sep; 39(3):352-61. PubMed ID: 20452425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.